Table 2 Characteristics of patients.

From: PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4–10 ng/ml

Variable

Training (n = 323)

Validation (n = 130)

csPCa (n = 87)

Non-csPCa (n = 236)

P

csPCa (n = 32)

Non-csPCa (n = 98)

P

Age (years, mean ± SD)

70.69 ± 8.73

67.89 ± 8.14

0.004

68.25 ± 8.79

67.84 ± 7.84

0.40

PSA (ng/mL, median [IQR])

6.74 (5.41–8.23)

6.86 (5.26–8.50)

0.63

7.13 (5.93–8.08)

6.81 (5.17–8.00)

0.26

PV (ml, median [IQR])

35.01 (26.00–67.07)

53.56 (38.71–70.38)

 < 0.001

36.83 (26.50–50.98)

49.70 (36.22–70.00)

0.004

PSAD (ng/mL/mL, median [IQR])

0.18 (0.13–0.25)

0.13 (0.10–0.17)

 < 0.001

0.17 (0.13–0.27)

0.13 (0.09–0.18)

0.003

Gleason score

  

  ≤ 3 + 3

255

108

 3 + 4

26

13

 4 + 3

20

4

 4 + 4

12

1

  1. csPCa clinically significant prostate cancer, IQR interquartile range, PSA prostate-specific antigen, PSAD prostate-specific antigen density, PV prostate volume, SD standard deviation.
Back to article page